Mark Offerhaus is the founder of Micreos. Micreos has raised $12M in total funding. Based in Wageningen, The Netherlands.
Mark Offerhaus is the CEO of Micreos, a Dutch biotechnology company specializing in phage technology for targeted bacterial control. The company develops endolysin technology, including its Staphefekt™ SA.100, which selectively targets Staphylococcus aureus for conditions like eczema. Micreos recently secured €30 million in funding to accelerate the development of its endolysin technology and launch its Gladskin product in the USA.
Full founder directory · Investor directory · Company funding database · Fundraising library